MX2016013340A - Metodos para tratar hipersomnia. - Google Patents

Metodos para tratar hipersomnia.

Info

Publication number
MX2016013340A
MX2016013340A MX2016013340A MX2016013340A MX2016013340A MX 2016013340 A MX2016013340 A MX 2016013340A MX 2016013340 A MX2016013340 A MX 2016013340A MX 2016013340 A MX2016013340 A MX 2016013340A MX 2016013340 A MX2016013340 A MX 2016013340A
Authority
MX
Mexico
Prior art keywords
methods
treating hypersomnia
hypersomnia
treating
channel blocker
Prior art date
Application number
MX2016013340A
Other languages
English (en)
Inventor
Lien Lyndon
Original Assignee
Balance Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Balance Therapeutics Inc filed Critical Balance Therapeutics Inc
Publication of MX2016013340A publication Critical patent/MX2016013340A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proporcionan los métodos, formulaciones y regímenes de dosificación para tratar hipersomnia en un individuo. Por ejemplo, los métodos que se proporcionan en la presente comprenden la administración de un bloqueador del canal de cloruro GABAA. En ciertas modalidades, el bloqueador del canal de cloruro GABAA es pentilenotetrazol (PTZ).
MX2016013340A 2014-04-15 2015-04-14 Metodos para tratar hipersomnia. MX2016013340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461979918P 2014-04-15 2014-04-15
PCT/US2015/025696 WO2015160766A1 (en) 2014-04-15 2015-04-14 Methods for treating hypersomnia

Publications (1)

Publication Number Publication Date
MX2016013340A true MX2016013340A (es) 2017-02-09

Family

ID=54324484

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016013340A MX2016013340A (es) 2014-04-15 2015-04-14 Metodos para tratar hipersomnia.

Country Status (12)

Country Link
US (3) US10688103B2 (es)
EP (1) EP3131904A4 (es)
JP (2) JP6672264B2 (es)
KR (1) KR20170005415A (es)
CN (1) CN106459066B (es)
AU (2) AU2015247829B2 (es)
CA (1) CA2945705A1 (es)
EA (1) EA201692061A1 (es)
IL (1) IL248255A0 (es)
MX (1) MX2016013340A (es)
WO (1) WO2015160766A1 (es)
ZA (1) ZA201607068B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10278977B2 (en) 2016-06-06 2019-05-07 Umecrine Cognition Ab Methods for treating hypersomnolence
WO2018209119A1 (en) * 2017-05-10 2018-11-15 Emory University Treatment of conditions associated with myotonic dystrophy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006137746A (ja) 2004-10-13 2006-06-01 Otsuka Pharmaceut Factory Inc オレキシン誘導組成物
ES2573733T3 (es) 2006-05-22 2016-06-09 The Board Of Trustees Of The Leland Stanford Junior University Tratamiento farmacológico del deterioro cognitivo
US20110038850A1 (en) 2007-01-05 2011-02-17 Didier Bagnol G Protein-Coupled Receptor and Modulators Thereof For The Treatment of Gaba-Related Neurological Disorders Including Sleep-Related Disorders
WO2009114740A2 (en) * 2008-03-12 2009-09-17 Emory University USE OF GABAa RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS
US20090325999A1 (en) * 2008-06-27 2009-12-31 Jie Du Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US8946206B2 (en) * 2010-12-17 2015-02-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for improving cognitive function
RU2013139247A (ru) 2011-02-23 2015-03-27 Церулеус Лтд. Комплексы флумазенила, содержащие их композиции и их применения
EP2705013B1 (en) 2011-05-04 2016-03-30 Balance Therapeutics, Inc. Pentylenetetrazole derivatives

Also Published As

Publication number Publication date
US20180169107A1 (en) 2018-06-21
IL248255A0 (en) 2016-11-30
US10688103B2 (en) 2020-06-23
US20200360398A1 (en) 2020-11-19
US20230115839A1 (en) 2023-04-13
JP2020105200A (ja) 2020-07-09
ZA201607068B (en) 2023-01-25
AU2019268190A1 (en) 2019-12-12
CA2945705A1 (en) 2015-10-22
EA201692061A1 (ru) 2017-03-31
AU2015247829A1 (en) 2016-10-27
JP6672264B2 (ja) 2020-03-25
CN106459066A (zh) 2017-02-22
EP3131904A1 (en) 2017-02-22
AU2015247829B2 (en) 2019-12-05
CN106459066B (zh) 2020-07-07
EP3131904A4 (en) 2017-11-22
KR20170005415A (ko) 2017-01-13
WO2015160766A1 (en) 2015-10-22
JP2017511386A (ja) 2017-04-20

Similar Documents

Publication Publication Date Title
EP3137606A4 (en) METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
ZA201608164B (en) Systems, apparatus, and methods for generating and analyzing resistome profiles
SG11201605692WA (en) Audio processing device and method, and program therefor
SG11201608543RA (en) Systems, apparatus and methods for improved authentication
IL281682A (en) Roller kit, pipe components and method
SG10201900574SA (en) Virtual currency conversion device, method and computer program
GB2587284B (en) Well ranging apparatus. methods, and systems
EP3125221A4 (en) Encryption processing device, and encryption processing method and program
HUE064331T2 (hu) Benzoimidazol-1,2-il amidok mint KV7 csatorna aktivátorok
GB2549200B (en) Well ranging apparatus, methods and systems
ZA201703498B (en) Kcnq2-5 channel activator
EP3106218A4 (en) Carbon-dioxide capturing material, and carbon-dioxide recovery apparatus using same
TW201613587A (en) Medical treatments based on anamorelin
GB2556477B (en) Irrigation apparatus and feeding system
MX2016009537A (es) Metodo para tratar ropa.
LT3405213T (lt) Bakteriniai šešėliai, skirti panaudoti vėžio gydyme
GB2557757B (en) Irrigation apparatus and feeding system
GB201405715D0 (en) Methods, apparatus and materials
AU2019268190A1 (en) Methods for treating hypersomnia
IL248807B (en) Kv1.3 potassium channel antagonists
SG11201702148RA (en) Acrylic acid-based copolymer, method for producing same and water treatment agent
GB201400767D0 (en) Devices, systems and methods for the whitening of teeth
ZA201605538B (en) Channel decoding method and apparatus, and distributed decoder
PH12017500071A1 (en) Therapeutic agent for keratoconjunctive disorder
MX2016009541A (es) Metodo para tratar vajilla.